The Centers for Disease Control and Prevention (CDC) said on Monday it had ended its COVID-19 country travel health notices as fewer countries reported enough data for accurate assessments.
If you are not happy with the results below please do another search
50 search results for:
Grifols appointed an executive chairman on Monday, as the Spanish pharmaceutical company strives to recover from a pandemic-related hit and a 49% drop in its shares so far this year.
The U.S. Supreme Court on Monday declined to hear a challenge by Missouri and nine other states – mostly Republican-led – to President Joe Biden’s COVID-19 vaccine mandate for workers in healthcare facilities that receive federal funds.
Through its Alexion subsidiary, AstraZeneca is acquiring Lexington, Mass.-based LogicBio Therapeutics in a deal worth $68 million. The deal bolsters AstraZeneca’s efforts in genomics and rare diseases.
The U.S. Supreme Court on Monday declined to hear Biogen Inc’s (BIIB.O) bid to win reinstatement of a patent on the company’s blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc. subsidiary (VTRS.O) Mylan Pharmaceuticals Inc.
Say what you will about the $158,000 price tag on Amylyx’s newly minted Relyvrio or the worthiness of the CENTAUR trial, the FDA’s approval of its third-ever ALS drug has ignited the growing momentum in the space.
Myovant Sciences announced Sunday it formed a special committee of independent directors to assess Sumitovant Biopharma’s offer to acquire the company, and ultimately, turned the offer down.
Swedish geneticist Svante Paabo won the 2022 Nobel Prize in Physiology or Medicine on Monday for discoveries that underpin our understanding of how modern day humans evolved from extinct ancestors.
LEO Pharma A/S, a global leader in medical dermatology, has launched AD Days Around the World, a global disease awareness campaign that highlights the experiences of people living with atopic dermatitis (AD) – the most common form of eczema.
Moderna Inc. has refused to hand over to China the core intellectual property behind the development of its COVID-19 vaccine, leading to a collapse in negotiations on its sale there, the Financial Times reported on Saturday, citing people familiar with the matter.